Skip to content

The efficacy and safety of enhanced external counterpulsation combined with intravenous thrombolysis in the treatment of acute ischemic stroke:A randomized controlled trial

A randomized, double-blind controlled trial on the efficacy and safety of enhanced external counterpulsation combined with intravenous thrombolysis in the treatment of acute ischemic stroke

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080746
Enrollment
Unknown
Registered
2024-02-06
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Interventions

Treatment group:EECP
Control group:Sham EECP stimulation

Sponsors

The Second People's Hospital of Hefei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? The diagnostic criteria of AIS were in line with the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018; ? AIS patients were admitted to hospital within 4.5 h of onset and received intravenous infusion of rt-PA; ? Independent daily life before symptom onset, modified Rankin scale (mRS)=2; ? National Institutes of Health Stroke Scale (NIHSS) score = 20; ? All patients included in the study agreed to participate and signed informed consent.

Exclusion criteria

Exclusion criteria: ? mRS Score =2 points after intravenous thrombolysis; ? Previous brain disease, including intracranial aneurysm or arteriovenous malformation, brain surgery or hemorrhagic stroke, dementia ? Previous major diseases: cancer, serious heart disease (left ventricular ejection fraction < 40%, valvular heart disease), acute and chronic severe renal insufficiency; ? cardiogenic cerebral embolism; ? Uncontrolled hypertension (blood pressure =180/100 mmHg); ? Implantable pacemakers, drug pumps and brain stimulators; ? Deep venous thrombosis or coagulation dysfunction of lower limbs.

Design outcomes

Primary

MeasureTime frame
mRS score;Mortality;sICH;END;

Secondary

MeasureTime frame
Barthel;The average blood flow velocity of bilateral anterior, middle, and posterior cerebral arteries, as well as the vertebrobasilar artery;

Countries

China

Contacts

Public ContactLong Wang

The Second People's Hospital of Hefei

guxindao606@163.com+86 159 5600 0543

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026